⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of NX-1607 in Adults With Advanced Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of NX-1607 in Adults With Advanced Malignancies

Official Title: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Study ID: NCT05107674

Interventions

NX-1607
Paclitaxel

Study Description

Brief Summary: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Detailed Description: Phase 1a will consist of 2 study arms: Monotherapy and Paclitaxel combo. Phase 1a dose escalation will evaluate the safety and tolerability of NX-1607 in adult patients with advanced solid tumors for which standard therapy with proven clinical benefit does not exist, is no longer effective, or is not appropriate. Indications for monotherapy include platinum resistant epithelial ovarian cancer (EOC), gastric/gastroesophageal junction (GEJ) cancer, squamous cell carcinoma of the head and neck (HNSCC), recurrent and either metastatic or unresectable melanoma, non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer (mCRPC), malignant pleural mesothelioma (MPM), triple-negative breast cancer (TNBC), locally advanced or metastatic urothelial cancer, cervical cancer, and microsatellite stable colorectal cancer (MSS CRC), and diffuse large cell B-cell lymphoma (DLBCL) including patients with Richter transformation (DLBCL-RT). Indications for paclitaxel combo may include, but are not limited to, platinum-resistant EOC, gastric/GEJ cancer, HNSCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer, and cervical cancer at the Sponsor's discretion. Phase 1b will investigate the efficacy of NX-1607 as monotherapy or in combination with paclitaxel at the dose(s) selected in Phase 1a in up to 8 cohorts of patients with select advanced malignancies for which standard therapy, including immunotherapy, with proven clinical benefit does not exist, is no longer effective, or is not appropriate. Indications include platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma, advanced gastric/GEJ cancer, HNSCC, recurrent and either metastatic or unresectable melanoma, advanced NSCLC, mCRPC, mixed solid tumor cohort indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or MSS CRC, and DLBCL including patients with DLBCL-RT.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

City of Hope, Duarte, California, United States

University of Southern California, Los Angeles, California, United States

University of California, San Francisco, San Francisco, California, United States

University of Colorado School of Medicine, Aurora, Colorado, United States

University of Chicago, Chicago, Illinois, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

University of North Carolina, Chapel Hill, North Carolina, United States

University of Oklahoma, Oklahoma City, Oklahoma, United States

MD Anderson Cancer Center, Houston, Texas, United States

University of Virginia, Charlottesville, Virginia, United States

Swedish Cancer Institute, Seattle, Washington, United States

Fred Hutchinson Cancer Center, Seattle, Washington, United States

Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom

University College London Hospitals NHS Foundation Trust, Bloomsbury, , United Kingdom

Addenbrookes Cambridge University Hospital, Cambridge, , United Kingdom

Beatson West of Scotland Cancer Centre, Glasgow, , United Kingdom

Sarah Cannon Research Institute, London, , United Kingdom

The Christie NHS Foundation Trust, Manchester, , United Kingdom

Northern Centre for Cancer Care, Newcastle, , United Kingdom

Churchill Hospital, Oxford, , United Kingdom

Contact Details

Name: Paula O'Connor, MD

Affiliation: Nurix Therapeutics, Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: